Moreover, CCL3 preferentially recruits pre-DCs to tumor locations, as antibody mediated neutralization of CCL3 does not result in a decrease in any other CD45+ leukocyte subset, nor does it alter the frequency of splenic pre-DCs (46). The gene discussed is CCL3; the disease is neoplasm.